Telomir Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Quarterly Report (Form 10-Q) | 14 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Lead Candidate IND Status Quarterly1.0Target: Initiation of Phase 1/2 clinical trial
Cash Runway (Quarters) Quarterly3.0Target: Extend runway beyond Q1 2027
Watch Items
- Phase 1/2 Clinical Trial Initiation for Telomir-Zn in TNBCTrigger: First-in-human dosing milestoneAction: Evaluate initial safety, tolerability, and pharmacokinetics data to de-risk clinical development.
- Cash Burn Rate and Capital RaisesTrigger: Cash balance falling below $3.0 millionAction: Assess dilution risk from ATM program or private placements to sustain operations past Q1 2027.
Research as of 19 Jun 2026